New paradigms for treatment development
- PMID: 17673495
- PMCID: PMC2632353
- DOI: 10.1093/schbul/sbm085
New paradigms for treatment development
Abstract
Wayne Fenton believed that government-particularly National Institute of Mental Health (NIMH)-could play a critical role in addressing important public health problems where the current system of treatment development was inadequate. Earlier experiences in HIV/AIDS convinced him and others that the NIMH can effectively facilitate the rapid development of new research in critical areas. This report will demonstrate how the work of Fenton and others brought together representatives from industry, government, and academia to address issues that included new preclinical approaches to drug development and defining new therapeutic targets in schizophrenia. An initiative to facilitate the development of new pharmacological agents to address the cognitive impairments in schizophrenia-titled Measurement and Treatment Research to Improve Cognition in Schizophreniaor MATRICS-is used as an example of a new paradigm for treatment development.
References
-
- Hegarty JD. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:1409–1416. - PubMed
-
- United States Government Accountability Office. New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts. Washington, DC: United States Government Accountability Office; 2006.
-
- Owens J. 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2006;6:99–101. - PubMed
-
- Group N.M.H.P.T. The NIMH Multisite HIV Prevention Trial: reducing HIV sexual risk behavior. Science. 1997;280:1889–1894. - PubMed
-
- Coutinho R. Interventions to prevent HIV risk behaviors. AIDS. 2000;14(Suppl 2):1–96. - PubMed
Publication types
MeSH terms
Substances
Personal name as subject
- Actions
LinkOut - more resources
Full Text Sources
Medical